Genetically Engineered Stem Cells May Revolutionize Parkinson's Disease Treatment

The future treatment of Parkinson’s Disease has undergone tremendous development in recent years. Now, a breakthrough in research has emerged, delivering the strongest results for both side-effect-free and long-lasting treatment effects.

The results are just published in Nature Communications under the title "Enhanced production of mesencephalic dopaminergic neurons from lineage-restricted human undifferentiated stem cells."

In the new research findings, DANDRITE group leader and Associate Professor Mark Denham has developed a method that ensures much higher purity of the so-called dopamine cells, which are crucial in connection with Parkinson's disease.

Stem cells offer promising potential for treating Parkinson's disease by transforming into specific nerve cells. However, the precision of this transformation poses a significant challenge with current methods, resulting in low purity."

Mark Denham, Associate Professor, Aarhus University

Achieving high purity is critical for effectively restoring movement in patients.

In the Denham Lab, stem cells were genetically engineered to prevent them from generating the incorrect types of nerve cells. The newly engineered stem cells have an enhanced ability to produce the specific nerve cells required for Parkinson's treatment known as the dopaminergic cells.

Furthermore, the researchers show that the genetically engineered stem cells led to the restoration of movement in animal models. This breakthrough is a potential new therapeutic approach for treating Parkinson's disease patients.

Experiments on rats have shown that both the quantity and purity of cultured stem cells are critical for the number and duration of treatments.

"Using our genetically engineered cells we generate a higher purity of dopamine cells, for patients this will reduce the recovery time and diminish the risk of relapse and medication use. My goal is to help patients stay off their medication, which requires high purity. So, my next step is to transfer my method to clinical trials," Marks states.

Source:
Journal reference:

Maimaitili, M., et al. (2023). Enhanced production of mesencephalic dopaminergic neurons from lineage-restricted human undifferentiated stem cells. Nature Communications. doi.org/10.1038/s41467-023-43471-0.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Research Sheds Light on the Evolution of Skin Appendages